GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: FX 909 | FX909
Compound class:
Synthetic organic
Comment: FX-909 is a first-in-class oral, covalent inverse agonist of the peroxisome proliferator activated receptor gamma (PPARG) nuclear hormone receptor [2]. It was developed for anti-tumour potential. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| FX-909 is a clinical candidate for solid tumours and urothelial carcinoma. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05929235 | A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Phase 1 Interventional | Flare Therapeutics Inc. | 1 | |